Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

In two phase 3, double-blind, placebo-controlled trials, the Janus kinase inhibitor ruxolitinib showed superiority to vehicle control in facial repigmentation of vitiligo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-10, Vol.387 (16), p.1445-1455
Hauptverfasser:	Rosmarin, David, Passeron, Thierry, Pandya, Amit G., Grimes, Pearl, Harris, John E., Desai, Seemal R., Lebwohl, Mark, Ruer-Mulard, Mireille, Seneschal, Julien, Wolkerstorfer, Albert, Kornacki, Deanna, Sun, Kang, Butler, Kathleen, Ezzedine, Khaled
Format:	Artikel
Sprache:	eng
Schlagworte:	Acne Acne Vulgaris - chemically induced Administration, Topical Adolescent Medicine Adult Adverse events Allergy Autoimmune Disease Autoimmune diseases Clinical Medicine Clinical Medicine General Clinical trials Clinical Trials, Phase III as Topic Dermatology Dermatology General Double-Blind Method Enzyme inhibitors Human health and pathology Humans Immunology Immunology General Inflammatory Disease Inhibitor drugs Janus kinase Janus Kinases - antagonists & inhibitors Life Sciences Likert scale Nitriles - administration & dosage Nitriles - adverse effects Nitriles - therapeutic use Patients Pediatrics Pruritus Pruritus - chemically induced Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Randomized Controlled Trials as Topic Rhinopharyngitis Skin Skin Cream - administration & dosage Skin Cream - adverse effects Skin Cream - therapeutic use Skin diseases Statistical analysis Teenagers Treatment Outcome Vitiligo Vitiligo - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In two phase 3, double-blind, placebo-controlled trials, the Janus kinase inhibitor ruxolitinib showed superiority to vehicle control in facial repigmentation of vitiligo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2118828